Carcinoma subseroso de la vesícula biliar: expresión del complejo caderina-catenina

ROA E, IVÁN; IBACACHE S, GILDA; Melo A, Angélica; Morales M, Erick; Villaseca H, Miguel; Araya O, Juan; Roa S, Juan; GUZMÁN G, PABLO; DE ARETXABALA U, XABIER


"Background: Subserous gallbladder carcinoma is difficult to diagnose and treat. There are no tissue markers with prognostic value in this type of tumor. Aim: To study the immunohistochemical expression of E-cadherin alpha and beta catenin in subserous gallbladder carcinoma. Patients and methods: One hundred seventeen subjects (103 women and 14 men aged 62 and 69 years as a mean, respectively), were studied. Thirty five gallbladder samples without evidence of cancer were used as controls. Expression of markers was studied with standard immunohistochemical techniques for formalin fixed and paraffin embedded tissue. Results: Ninety seven percent of tumors were adenocarcinoma. A lower or absent expression of E-cadherin, alpha catenin and beta catenin was observed in 26, 33 and 29% of tumors, respectively. Actuarial five years survival was 37%. No association between macroscopic features of the tumor and survival was observed. Well differentiated tumors had a 73% survival, whereas less differentiated tumors had a 30% survival. Tumors with a normal expression of the markers had a slightly better survival, although not significant (p=0.06). Conclusions: Approximately 30% of subserous gallbladder carcinoma have an abnormal expression of E-cadherin, alpha catenin and beta catenin. This abnormal expression has no relationship with prognosis and is probably secondary to the aberrant genic expression of the tumor (Rev M

Más información

Título según WOS: ID SCIELO:S0034-98872002001200004 Not found in local WOS DB
Título según SCIELO: Carcinoma subseroso de la vesícula biliar: expresión del complejo caderina-catenina
Título de la Revista: REVISTA MEDICA DE CHILE
Volumen: 130
Número: 12
Editorial: Sociedad Médica de Santiago
Fecha de publicación: 2002
Página de inicio: 1349
Página final: 1357
Idioma: es